Compare Commvault Systems Inc (CVLT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs Novo Nordisk A/S — how do they compare? Commvault Systems Inc trades at $156.34 (market cap $6.25B), while Novo Nordisk A/S trades at $38.63 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 26.4× Commvault Systems Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Commvault Systems Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Novo Nordisk A/S for 116 Days on average.
| CVLT | NVO | |
|---|---|---|
Market Cap | $6.25B | $165.31B |
Volume | 632,727 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $176.52 | $63.98 |
52-Week Low | $75.18 | $35.29 |
Typical Hold Time | 17 Days | 116 Days |
Enterprise Value | $6.24B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Commvault Systems (CVLT) trades at $155.16, up 3.25% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $1.42 exceeding expectations, though valuation metrics remain elevated with a P/E of 96.73. Recent positive developments include AWS Data Competency achievement and expanded FedRAMP authorization, supporting the company's AI-focused resilience platform.
CVLT presents growth potential through its AI integration and cloud partnerships, but faces risks from high valuation multiples and declining profit margins. With 54.55% analyst buy ratings and a $156.55 consensus target, the stock appears fairly valued near current levels, requiring careful monitoring of execution against growth expectations.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
